<DOC>
	<DOCNO>NCT01205321</DOCNO>
	<brief_summary>Visual assessment diagnostic PET/CT ( positron emission tomography/computed tomography ) image obtain single intravenous injection BAY86-7548 patient cancer .</brief_summary>
	<brief_title>PET/CT Imaging Radiation Dosimetry , Plasma Pharmacokinetics , Biodistribution , Safety Tolerability Diagnostic Performance BAY86-7548 Patients With Prostate Cancer Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Bombesin</mesh_term>
	<mesh_term>Gastrin-Releasing Peptide</mesh_term>
	<criteria>Healthy volunteer : male , &gt; /=50 &lt; /= 65 year age Cancer patient : male &gt; /= 45 year age Patients MRI prostate and/or positive choline acetate PET/CT diagnosis ( Note : MRI , choline acetate PET/CT optional primary prostate cancer patient ) recurrence prostate cancer primary cancer disease is/ histologically confirm . The prostate cancer histologically confirm result histology available . Patients primary prostate cancer : &gt; /= 20 percent biopsy material affect cancer histopathological evaluation . Patients primary prostate cancer : Patient schedule undergo prostatectomy . Concurrent severe and/or uncontrolled and/or unstable medical disease ( e.g . poorly control diabetes , congestive heart failure , myocardial infarction within 12 month prior plan injection BAY867548 , unstable uncontrolled hypertension , chronic renal hepatic disease , severe pulmonary disease ) could compromise participation study Known sensitivity study drug component preparation .</criteria>
	<gender>Male</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Neoplasm</keyword>
	<keyword>PET/CT diagnosis</keyword>
	<keyword>PET tracer</keyword>
</DOC>